常用商品分类
提示：当前页面内容为订单快照，包含订单创建时的商品详情和下单信息等，在发生交易争议时，该页面可作为判定依据。服务电话(移)：17319309550
DeepBio得分:5567.2
DeepBio得分
是基于文献引用次数，影响因子，文献新近度等因素计算的客观产品评级，得分越高表明该产品经过越可靠的实验验证，质量可信度越高
≥98% (HPLC)
329826065
DMSO: 5 mg/mL, clear (warmed)
LJI308 is potent pan-RSK inhibitor that targets RSK N-terminal kinase domain (NTKD) ATP-binding site (IC₅₀/[ATP] = 6 nM/5 μM/RSK1, 4 nM/20 μM/RSK2, 13 nM/10 μM/RSK3), exhibiting similary binding affinity toward RSK1-4, but much reduced inhibitory potency against S6K1 (IC₅₀ = 0.8 μM), MEK4 (IC₅₀ >10 μM), and HIP kinase 1 (IC₅₀ >1 μM). LJI308 effectivelfy reduces cellular Y-box binding protein-1 (YB1) Ser102 (EC₅₀ = 0.2-0.3 μM; MDA-MB-231 and H358 cells), but not ribosomal S6 protein (S6RP) S235/236, phosphorylation level and selectively inhibits the growth of YB1-overpressing HTRY-LT triple-negative breast cancer (TNBC) cells, but not the parental non-tumorigenic human mammary epithelial cell (HMEC) line HTRZ (% inhibition = 6.8%/HTRZ, 88%/HTRY-LT1, 66%/HTRY-LT2 in 8 days; 5 μM at 0 and 96 hr).
| 好评度 | 商品满意度 | 服务满意度 | 发货满意度 |
"SML1788-5MG，LJI308"商品可能已被商家删除，您可查看其他相似商品！
相似产品推荐
购物车（0）
分类纠错
举报
纠错
收 藏
比价
线下结算
公务卡
网银支付
微信
支付宝